Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02877927 is registered in ClinicalTrials.gov with Paratek Pharmaceuticals Inc as lead sponsor.

NCT NCT02877927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02877927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Lead sponsor
Paratek Pharmaceuticals Inc
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2016
Completion date
June 6, 2017
Enrollment
735 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infections, skin structures and soft tissue infections